关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
& [3 L. E1 H- \5 U% R8 f# [  n3 c    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。

' e, i+ }. @1 _- b. i5 w作者：来自澳大利亚
来源：Haematologica. 2011.8.9.
- B, K! {" d$ `9 YDear Group,

Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML
, q1 i0 D) ?2 g1 C5 d' `therapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
1 h6 M+ X1 {  i  E# C0 u* \* |remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
3 |0 d' ~5 I! {" f6 m4 Z' W% F3 E. f: bdoes spike up the immune system so I hope more reports come out on this issue.
/ o( ~3 J$ F6 I4 h  H
- ^: `' x# F4 b0 v2 E0 }/ H, s5 NThe remarkable news about Sprycel cessation is that all 3 patients had failed
Gleevec and Sprycel was their second TKI so they had resistant disease. This is
different from the stopping Gleevec trial in France which only targets patients
) q" m' I5 X& O, J( S+ ?who have done well on Gleevec.

Hopefully, the doctors will report on a larger study and long-term to see if the
response off Sprycel is sustained.
7 X' G$ q9 G# _1 T4 v# P
Best Wishes,
9 _" G1 t$ @0 ]) T: J$ t! Q( F* V0 vAnjana


# j$ g( h! t1 T4 U2 A, E
Haematologica. 2011 Aug 9. [Epub ahead of print]
Durable complete molecular remission of chronic myeloid leukemia following
! I3 a- c0 v" Odasatinib cessation, despite adverse disease features.
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
: \. Q* Q" ~8 ^Source
$ D- t9 f$ b5 {! u6 s9 m3 G; D6 JAdelaide, Australia;
4 n% ?  `! p9 O( O
+ {& C% G' A2 tAbstract
Patients with chronic myeloid leukemia, treated with imatinib, who have a
! H+ i/ [6 N& l( bdurable complete molecular response might remain in CMR after stopping
treatment. Previous reports of patients stopping treatment in complete molecular
  K+ L  {$ y6 C# w/ k* S) x3 X) qresponse have included only patients with a good response to imatinib. We
0 y4 ^2 O2 D+ X, C$ M6 rdescribe three patients with stable complete molecular response on dasatinib
) X! R1 P3 h5 Ctreatment following imatinib failure. Two of the three patients remain in
complete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
9 t% i& z  t0 h$ e( d! sshow that the leukemic clone remains detectable, as we have previously shown in
+ S% n2 F2 [- J8 J" ?3 I5 M% `imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
who relapsed and in one patient in remission. Our results suggest that the
3 ]3 ?' E" A) acharacteristics of complete molecular response on dasatinib treatment may be
' k1 @0 r4 C  R; I+ p6 v8 dsimilar to that achieved with imatinib, at least in patients with adverse
; o3 d. _; `/ b+ edisease features.
% Q; H# G9 s8 C8 T$ ]/ X' H

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。

作者：来自法国STIM试验
- Q/ L& h) n/ @. f$ N% O3 k- K来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事